1
|
Oh KK, Eom JA, Lee KJ, Kwon GH, Yoon SJ, Song SH, Park JH, Kim JS, Kim DJ, Suk KT. The epitome of tailor-made short positively charged peptides against HCC via integrated pharmacology. J Transl Med 2024; 22:279. [PMID: 38491465 PMCID: PMC10941355 DOI: 10.1186/s12967-024-05087-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2024] [Accepted: 03/11/2024] [Indexed: 03/18/2024] Open
Affiliation(s)
- Ki-Kwang Oh
- Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea
| | - Jung-A Eom
- Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea
| | - Kyeong Jin Lee
- Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea
| | - Goo-Hyun Kwon
- Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea
| | - Sang-Jun Yoon
- Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea
| | - Seol Hee Song
- Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea
| | - Jeong Ha Park
- Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea
| | - Jeong Su Kim
- Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea
| | - Dong Joon Kim
- Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea
| | - Ki-Tae Suk
- Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea.
| |
Collapse
|
2
|
Oh KK, Yoon SJ, Eom JA, Lee KJ, Kwon GH, Kim DJ, Suk KT. A strategy to pioneer key agent(s) in Cephalotaxus alkaloids against pan-cancer via filtering methodology based on integrated pharmacology. J Transl Med 2024; 22:262. [PMID: 38462631 PMCID: PMC10926570 DOI: 10.1186/s12967-024-05059-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2024] [Accepted: 03/04/2024] [Indexed: 03/12/2024] Open
Affiliation(s)
- Ki-Kwang Oh
- Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea
| | - Sang-Jun Yoon
- Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea
| | - Jung-A Eom
- Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea
| | - Kyeong Jin Lee
- Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea
| | - Goo-Hyun Kwon
- Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea
| | - Dong Joon Kim
- Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea
| | - Ki-Tae Suk
- Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea.
| |
Collapse
|
3
|
Oh KK, Gupta H, Ganesan R, Sharma SP, Won SM, Jeong JJ, Lee SB, Cha MG, Kwon GH, Jeong MK, Min BH, Hyun JY, Eom JA, Park HJ, Yoon SJ, Choi MR, Kim DJ, Suk KT. The seamless integration of dietary plant-derived natural flavonoids and gut microbiota may ameliorate non-alcoholic fatty liver disease: a network pharmacology analysis. Artif Cells Nanomed Biotechnol 2023; 51:217-232. [PMID: 37129458 DOI: 10.1080/21691401.2023.2203734] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
We comprised metabolites of gut microbiota (GM; endogenous species) and dietary plant-derived natural flavonoids (DPDNFs; exogenous species) were known as potent effectors against non-alcoholic fatty liver disease (NAFLD) via network pharmacology (NP). The crucial targets against NAFLD were identified via GM and DPDNFs. The protein interaction (PPI), bubble chart and networks of GM or natural products- metabolites-targets-key signalling (GNMTK) pathway were described via R Package. Furthermore, the molecular docking test (MDT) to verify the affinity was performed between metabolite(s) and target(s) on a key signalling pathway. On the networks of GNMTK, Enterococcus sp. 45, Escherichia sp.12, Escherichia sp.33 and Bacterium MRG-PMF-1 as key microbiota; flavonoid-rich products as key natural resources; luteolin and myricetin as key metabolites (or dietary flavonoids); AKT Serine/Threonine Kinase 1 (AKT1), CF Transmembrane conductance Regulator (CFTR) and PhosphoInositide-3-Kinase, Regulatory subunit 1 (PIK3R1) as key targets are promising components to treat NAFLD, by suppressing cyclic Adenosine MonoPhosphate (cAMP) signalling pathway. This study shows that components (microbiota, metabolites, targets and a key signalling pathway) and DPDNFs can exert combinatorial pharmacological effects against NAFLD. Overall, the integrated pharmacological approach sheds light on the relationships between GM and DPDNFs.
Collapse
Affiliation(s)
- Ki-Kwang Oh
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Haripriya Gupta
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Raja Ganesan
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Satya Priya Sharma
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Sung-Min Won
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Jin-Ju Jeong
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Su-Been Lee
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Min-Gi Cha
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Goo-Hyun Kwon
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Min-Kyo Jeong
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Byeong-Hyun Min
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Ji-Ye Hyun
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Jung-A Eom
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Hee-Jin Park
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Sang-Jun Yoon
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Mi-Ran Choi
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Dong Joon Kim
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| | - Ki-Tae Suk
- Center for Microbiome, Institute for Liver and Digestive Diseases, Hallym University Medical Center, Chuncheon, Korea
| |
Collapse
|
4
|
Oh KK, Choi I, Gupta H, Raja G, Sharma SP, Won SM, Jeong JJ, Lee SB, Cha MG, Kwon GH, Jeong MK, Min BH, Hyun JY, Eom JA, Park HJ, Yoon SJ, Choi MR, Kim DJ, Suk KT. New insight into gut microbiota-derived metabolites to enhance liver regeneration via network pharmacology study. Artif Cells Nanomed Biotechnol 2023; 51:1-12. [PMID: 36562095 DOI: 10.1080/21691401.2022.2155661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
We intended to identify favourable metabolite(s) and pharmacological mechanism(s) of gut microbiota (GM) for liver regeneration (LR) through network pharmacology. We utilized the gutMGene database to obtain metabolites of GM, and targets associated with metabolites as well as LR-related targets were identified using public databases. Furthermore, we performed a molecular docking assay on the active metabolite(s) and target(s) to verify the network pharmacological concept. We mined a total of 208 metabolites in the gutMGene database and selected 668 targets from the SEA (1,256 targets) and STP (947 targets) databases. Finally, 13 targets were identified between 61 targets and the gutMGene database (243 targets). Protein-protein interaction network analysis showed that AKT1 is a hub target correlated with 12 additional targets. In this study, we describe the potential microbe from the microbiota (E. coli), chemokine signalling pathway, AKT1 and myricetin that accelerate LR, providing scientific evidence for further clinical trials.
Collapse
Affiliation(s)
- Ki-Kwang Oh
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Ickwon Choi
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Haripriya Gupta
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Ganesan Raja
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Satya Priya Sharma
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Sung-Min Won
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Jin-Ju Jeong
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Su-Been Lee
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Min-Gi Cha
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Goo-Hyun Kwon
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Min-Kyo Jeong
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Byeong-Hyun Min
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Ji-Ye Hyun
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Jung-A Eom
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Hee-Jin Park
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Sang-Jun Yoon
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Mi-Ran Choi
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Dong Joon Kim
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| | - Ki-Tae Suk
- Hallym University College of Medicine, Institute for Liver and Digestive Diseases, Chuncheon, Korea
| |
Collapse
|
5
|
Oh KK, Yoon SJ, Lee SB, Lee SY, Gupta H, Ganesan R, Sharma SP, Won SM, Jeong JJ, Kim DJ, Suk KT. The convergent application of metabolites from Avena sativa and gut microbiota to ameliorate non-alcoholic fatty liver disease: a network pharmacology study. J Transl Med 2023; 21:263. [PMID: 37069607 PMCID: PMC10111676 DOI: 10.1186/s12967-023-04122-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2023] [Accepted: 04/09/2023] [Indexed: 04/19/2023] Open
Abstract
BACKGROUND Non-alcoholic fatty liver disease (NAFLD) is a serious public health issue globally, currently, the treatment of NAFLD lies still in the labyrinth. In the inchoate stage, the combinatorial application of food regimen and favorable gut microbiota (GM) are considered as an alternative therapeutic. Accordingly, we integrated secondary metabolites (SMs) from GM and Avena sativa (AS) known as potent dietary grain to identify the combinatorial efficacy through network pharmacology. METHODS We browsed the SMs of AS via Natural Product Activity & Species Source (NPASS) database and SMs of GM were retrieved by gutMGene database. Then, specific intersecting targets were identified from targets related to SMs of AS and GM. The final targets were selected on NAFLD-related targets, which was considered as crucial targets. The protein-protein interaction (PPI) networks and bubble chart analysis to identify a hub target and a key signaling pathway were conducted, respectively. In parallel, we analyzed the relationship of GM or AS─a key signaling pathway─targets─SMs (GASTM) by merging the five components via RPackage. We identified key SMs on a key signaling pathway via molecular docking assay (MDA). Finally, the identified key SMs were verified the physicochemical properties and toxicity in silico platform. RESULTS The final 16 targets were regarded as critical proteins against NAFLD, and Vascular Endothelial Growth Factor A (VEGFA) was a key target in PPI network analysis. The PI3K-Akt signaling pathway was the uppermost mechanism associated with VEGFA as an antagonistic mode. GASTM networks represented 122 nodes (60 GM, AS, PI3K-Akt signaling pathway, 4 targets, and 56 SMs) and 154 edges. The VEGFA-myricetin, or quercetin, GSK3B-myricetin, IL2-diosgenin complexes formed the most stable conformation, the three ligands were derived from GM. Conversely, NR4A1-vestitol formed stable conformation with the highest affinity, and the vestitol was obtained from AS. The given four SMs were no hurdles to develop into drugs devoid of its toxicity. CONCLUSION In conclusion, we show that combinatorial application of AS and GM might be exerted to the potent synergistic effects against NAFLD, dampening PI3K-Akt signaling pathway. This work provides the importance of dietary strategy and beneficial GM on NAFLD, a data mining basis for further explicating the SMs and pharmacological mechanisms of combinatorial application (AS and GM) against NAFLD.
Collapse
Affiliation(s)
- Ki-Kwang Oh
- Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea
| | - Sang-Jun Yoon
- Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea
| | - Su-Been Lee
- Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea
| | - Sang Youn Lee
- Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea
| | - Haripriya Gupta
- Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea
| | - Raja Ganesan
- Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea
| | - Satya Priya Sharma
- Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea
| | - Sung-Min Won
- Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea
| | - Jin-Ju Jeong
- Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea
| | - Dong Joon Kim
- Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea
| | - Ki-Tae Suk
- Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, 24252, Korea.
| |
Collapse
|
6
|
Ko DG, Park JW, Kim JH, Jung JH, Kim HS, Suk KT, Jang MK, Park SH, Lee MS, Kim DJ, Kim SE. Platelet-to-White Blood Cell Ratio: A Feasible Biomarker for Pyogenic Liver Abscess. Diagnostics (Basel) 2022; 12:diagnostics12102556. [PMID: 36292245 PMCID: PMC9600737 DOI: 10.3390/diagnostics12102556] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2022] [Revised: 10/11/2022] [Accepted: 10/11/2022] [Indexed: 11/29/2022] Open
Abstract
The platelet-to-white blood cell ratio (PWR) has been reported to predict the severity of patients with various diseases. However, no previous studies have assessed the use of the PWR as a prognostic marker for pyogenic liver abscesses (PLA). This observational retrospective study was performed between January 2008 and December 2017, including 833 patients with PLA from multiple centers. The enrolled patients, on average, had a PWR of 17.05, and 416 patients had a PWR lower than 17.05. A total of 260 patients (31.2%) with PLA showed complications of metastatic infection, pleural effusion and abscess rupture. A low PWR level was identified as a strong risk factor for metastatic infection and pleural effusion. The low PWR group also had a longer hospital stay. In the multivariate analysis, old age, anemia, albumin and CRP levels and unidentified pathogens were significant factors for low PWR levels. A low PWR, old age, male sex, abscess size, albumin, ALP and unidentified causative pathogens showed significant associations with a hospital stay longer than 28 days. As a result, PLA patients presenting with a low PWR were shown to have more complications and a poor prognosis. Considering its cost-effectiveness, PWR could be a novel biomarker used to predict a prognosis of PLA.
Collapse
Affiliation(s)
- Dong-Gyun Ko
- Department of Physiology, College of Medicine, Hallym University, Chuncheon 24252, Korea
| | - Ji-Won Park
- Department of Internal Medicine, Hallym University Sacred Heart Hospital, Medical Center, 22, Gwanpyeong-ro 170 Beon-gil, Anyang-si 14068, Korea
- Institute for Liver and Digestive Diseases, Hallym University, Chuncheon 24252, Korea
| | - Jung-Hee Kim
- Department of Internal Medicine, Dongtan Sacred Heart Hospital of Hallym University Medical Center, Hwaseong-si 18450, Korea
| | - Jang-Han Jung
- Department of Internal Medicine, Dongtan Sacred Heart Hospital of Hallym University Medical Center, Hwaseong-si 18450, Korea
| | - Hyoung-Su Kim
- Institute for Liver and Digestive Diseases, Hallym University, Chuncheon 24252, Korea
- Department of Internal Medicine, Kangdong Sacred Heart Hospital of Hallym University Medical Center, 18, Cheonho-daero 173-gil, Seoul 05355, Korea
| | - Ki-Tae Suk
- Institute for Liver and Digestive Diseases, Hallym University, Chuncheon 24252, Korea
- Department of Internal Medicine, Chuncheon Sacred Heart Hospital of Hallym University Medical Center, 77, Chuncheon-si 24253, Korea
| | - Myoung-Kuk Jang
- Institute for Liver and Digestive Diseases, Hallym University, Chuncheon 24252, Korea
- Department of Internal Medicine, Kangdong Sacred Heart Hospital of Hallym University Medical Center, 18, Cheonho-daero 173-gil, Seoul 05355, Korea
| | - Sang-Hoon Park
- Department of Internal Medicine, Kangnam Sacred Heart Hospital of Hallym University Medical Center, 1, Singil-ro, Seoul 07441, Korea
| | - Myung-Seok Lee
- Department of Internal Medicine, Kangnam Sacred Heart Hospital of Hallym University Medical Center, 1, Singil-ro, Seoul 07441, Korea
| | - Dong-Joon Kim
- Institute for Liver and Digestive Diseases, Hallym University, Chuncheon 24252, Korea
- Department of Internal Medicine, Chuncheon Sacred Heart Hospital of Hallym University Medical Center, 77, Chuncheon-si 24253, Korea
| | - Sung-Eun Kim
- Department of Internal Medicine, Hallym University Sacred Heart Hospital, Medical Center, 22, Gwanpyeong-ro 170 Beon-gil, Anyang-si 14068, Korea
- Institute for Liver and Digestive Diseases, Hallym University, Chuncheon 24252, Korea
- Correspondence: ; Tel.: +82-31-380-3708
| |
Collapse
|
7
|
Oh KK, Choi YR, Gupta H, Ganesan R, Sharma SP, Won SM, Jeong JJ, Lee SB, Cha MG, Kwon GH, Kim DJ, Suk KT. Identification of Gut Microbiome Metabolites via Network Pharmacology Analysis in Treating Alcoholic Liver Disease. Curr Issues Mol Biol 2022; 44:3253-3266. [PMID: 35877448 PMCID: PMC9316215 DOI: 10.3390/cimb44070224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2022] [Revised: 07/15/2022] [Accepted: 07/17/2022] [Indexed: 12/03/2022] Open
Abstract
Alcoholic liver disease (ALD) is linked to a broad spectrum of diseases, including diabetes, hypertension, atherosclerosis, and even liver carcinoma. The ALD spectrum includes alcoholic fatty liver disease (AFLD), alcoholic hepatitis, and cirrhosis. Most recently, some reports demonstrated that the pathogenesis of ALD is strongly associated with metabolites of human microbiota. AFLD was the onset of disease among ALDs, the initial cause of which is alcohol consumption. Thus, we analyzed the significant metabolites of microbiota against AFLD via the network pharmacology concept. The metabolites from microbiota were retrieved by the gutMGene database; sequentially, AFLD targets were identified by public databases (DisGeNET, OMIM). The final targets were utilized for protein–protein interaction (PPI) networks and signaling pathway analyses. Then, we performed a molecular docking test (MDT) to verify the affinity between metabolite(s) and target(s) utilizing the Autodock 1.5.6 tool. From a holistic viewpoint, we integrated the relationships of microbiota-signaling pathways-targets-metabolites (MSTM) using the R Package. We identified the uppermost six key targets (TLR4, RELA, IL6, PPARG, COX-2, and CYP1A2) against AFLD. The PPI network analysis revealed that TLR4, RELA, IL6, PPARG, and COX-2 had equivalent degrees of value (4); however, CYP1A2 had no associations with the other targets. The bubble chart showed that the PI3K-Akt signaling pathway in nine signaling pathways might be the most significant mechanism with antagonistic functions in the treatment of AFLD. The MDT confirmed that Icaritin is a promising agent to bind stably to RELA (known as NF-Κb). In parallel, Bacterium MRG-PMF-1, the PI3K-Akt signaling pathway, RELA, and Icaritin were the most significant components against AFLD in MSTM networks. In conclusion, we showed that the Icaritin–RELA complex on the PI3K-Akt signaling pathway by bacterial MRG-PMF-1 might have promising therapeutic effects against AFLD, providing crucial evidence for further research.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - Ki-Tae Suk
- Correspondence: ; Tel.: +82-10-5365-5700; Fax: +82-033-248-3481
| |
Collapse
|
8
|
Kim JH, Kim SE, Song DS, Kim HY, Yoon EL, Kim TH, Jung YK, Suk KT, Jun BG, Yim HJ, Kwon JH, Lee SW, Kang SH, Kim MY, Jeong SW, Jang JY, Yoo JJ, Kim SG, Jin YJ, Cheon GJ, Kim BS, Seo YS, Kim HS, Sinn DH, Chung WJ, Kim HY, Lee HA, Nam SW, Kim IH, Suh JI, Kim JH, Chae HB, Sohn JH, Cho JY, Kim YJ, Yang JM, Park JG, Kim W, Cho HC, Kim DJ. Platelet-to-White Blood Cell Ratio Is Associated with Adverse Outcomes in Cirrhotic Patients with Acute Deterioration. J Clin Med 2022; 11:jcm11092463. [PMID: 35566588 PMCID: PMC9103428 DOI: 10.3390/jcm11092463] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2022] [Revised: 04/23/2022] [Accepted: 04/24/2022] [Indexed: 02/05/2023] Open
Abstract
Background: The platelet-to-white blood cell ratio (PWR) is a hematologic marker of the systemic inflammatory response. Recently, the PWR was revealed to have a role as an independent prognostic factor for mortality in patients with hepatitis B virus (HBV)-related acute-on-chronic failure (ACLF) and HBV-related liver cirrhosis (LC) with acute decompensation (AD). However, the prognostic role of the PWR still needs to be investigated in LC patients with AD. In this study, we analyzed whether the PWR could stratify the risk of adverse outcomes (death or liver transplantation (LT)) in these patients. Methods: A prospective cohort of 1670 patients with AD of liver cirrhosis ((age: 55.2 ± 7.8, male = 1226 (73.4%)) was enrolled and evaluated for 28-day and overall adverse outcomes. Results: During a median follow-up of 8.0 months (range, 1.9−15.5 months), 424 (25.4%) patients had adverse outcomes (death = 377, LT = 47). The most common etiology of LC was alcohol use (69.7%). The adverse outcome rate was higher for patients with a PWR ≤ 12.1 than for those with a PWR > 12.1. A lower PWR level was a prognostic factor for 28-day adverse outcomes (PWR: hazard ratio 1.707, p = 0.034) when adjusted for the etiology of cirrhosis, infection, ACLF, and the MELD score. In the subgroup analysis, the PWR level stratified the risk of 28-day adverse outcomes regardless of the presence of ACLF or the main form of AD but not for those with bacterial infection. Conclusions: A lower PWR level was associated with 28-day adverse outcomes, indicating that the PWR level can be a useful and simple tool for stratifying the risk of 28-day adverse outcomes in LC patients with AD.
Collapse
Affiliation(s)
- Jung-Hee Kim
- Department of Internal Medicine, Hallym University College of Medicine, Chuncheon 24252, Korea; (J.-H.K.); (K.-T.S.); (H.-S.K.); (D.-J.K.)
- Institute for Liver and Digestive Diseases, Hallym University, Chuncheon 24252, Korea
| | - Sung-Eun Kim
- Department of Internal Medicine, Hallym University College of Medicine, Chuncheon 24252, Korea; (J.-H.K.); (K.-T.S.); (H.-S.K.); (D.-J.K.)
- Institute for Liver and Digestive Diseases, Hallym University, Chuncheon 24252, Korea
- Correspondence: ; Tel.: +82-31-380-3708
| | - Do-Seon Song
- Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea; (D.-S.S.); (H.-Y.K.); (J.-H.K.); (S.-W.L.); (J.-M.Y.)
| | - Hee-Yeon Kim
- Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea; (D.-S.S.); (H.-Y.K.); (J.-H.K.); (S.-W.L.); (J.-M.Y.)
| | - Eileen L. Yoon
- Department of Internal Medicine, Hanyang University College of Medicine, Seoul 04763, Korea; (E.L.Y.); (J.-H.S.)
| | - Tae-Hyung Kim
- Department of Internal Medicine, Korea University Ansan Hospital, Ansan 15355, Korea; (T.-H.K.); (Y.-K.J.); (H.-J.Y.); (Y.-S.S.); (J.-H.K.)
| | - Young-Kul Jung
- Department of Internal Medicine, Korea University Ansan Hospital, Ansan 15355, Korea; (T.-H.K.); (Y.-K.J.); (H.-J.Y.); (Y.-S.S.); (J.-H.K.)
| | - Ki-Tae Suk
- Department of Internal Medicine, Hallym University College of Medicine, Chuncheon 24252, Korea; (J.-H.K.); (K.-T.S.); (H.-S.K.); (D.-J.K.)
- Institute for Liver and Digestive Diseases, Hallym University, Chuncheon 24252, Korea
| | - Baek-Gyu Jun
- Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul 01757, Korea; (B.-G.J.); (S.-H.K.)
| | - Hyung-Joon Yim
- Department of Internal Medicine, Korea University Ansan Hospital, Ansan 15355, Korea; (T.-H.K.); (Y.-K.J.); (H.-J.Y.); (Y.-S.S.); (J.-H.K.)
| | - Jung-Hyun Kwon
- Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea; (D.-S.S.); (H.-Y.K.); (J.-H.K.); (S.-W.L.); (J.-M.Y.)
| | - Sung-Won Lee
- Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea; (D.-S.S.); (H.-Y.K.); (J.-H.K.); (S.-W.L.); (J.-M.Y.)
| | - Seong-Hee Kang
- Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul 01757, Korea; (B.-G.J.); (S.-H.K.)
| | - Moon-Young Kim
- Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju 26426, Korea;
| | - Soung-Won Jeong
- Department of Internal Medicine, Soonchunhyang University College of Medicine, Seoul 04401, Korea; (S.-W.J.); (J.-Y.J.)
| | - Jae-Young Jang
- Department of Internal Medicine, Soonchunhyang University College of Medicine, Seoul 04401, Korea; (S.-W.J.); (J.-Y.J.)
| | - Jeong-Ju Yoo
- Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon 14584, Korea; (J.-J.Y.); (S.-G.K.)
| | - Sang-Gyune Kim
- Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon 14584, Korea; (J.-J.Y.); (S.-G.K.)
| | - Young-Joo Jin
- Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, Incheon 22212, Korea;
| | - Gab-Jin Cheon
- Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung 25440, Korea;
| | - Byung-Seok Kim
- Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu 42472, Korea;
| | - Yeon-Seok Seo
- Department of Internal Medicine, Korea University Ansan Hospital, Ansan 15355, Korea; (T.-H.K.); (Y.-K.J.); (H.-J.Y.); (Y.-S.S.); (J.-H.K.)
| | - Hyung-Su Kim
- Department of Internal Medicine, Hallym University College of Medicine, Chuncheon 24252, Korea; (J.-H.K.); (K.-T.S.); (H.-S.K.); (D.-J.K.)
- Institute for Liver and Digestive Diseases, Hallym University, Chuncheon 24252, Korea
| | - Dong-Hyun Sinn
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06531, Korea;
| | - Woo-Jin Chung
- Department of Internal Medicine, Keimyung University School of Medicine, Daegu 42601, Korea;
| | - Hwi-Young Kim
- Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul 07804, Korea; (H.-Y.K.); (H.-A.L.)
| | - Han-Ah Lee
- Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul 07804, Korea; (H.-Y.K.); (H.-A.L.)
| | - Seung-Woo Nam
- Department of Internal Medicine, National Medical Center, Seoul 04564, Korea;
| | - In-Hee Kim
- Department of Internal Medicine, Chonbuk National University Hospital, Chonbuk National University Medical School, Jeonju 54896, Korea;
| | - Jung-Il Suh
- Department of Gastroenterology, Dongguk University College of Medicine, Kyongju 38067, Korea;
| | - Ji-Hoon Kim
- Department of Internal Medicine, Korea University Ansan Hospital, Ansan 15355, Korea; (T.-H.K.); (Y.-K.J.); (H.-J.Y.); (Y.-S.S.); (J.-H.K.)
| | - Hee-Bok Chae
- Department of Internal Medicine, Medical Research Institute, Chungbuk National University College of Medicine, Cheongju 28644, Korea;
| | - Joo-Hyun Sohn
- Department of Internal Medicine, Hanyang University College of Medicine, Seoul 04763, Korea; (E.L.Y.); (J.-H.S.)
| | - Ju-Yeon Cho
- Department of Internal Medicine, College of Medicine, Chosun University, Gwangju 61452, Korea;
| | - Yoon-Jun Kim
- Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine, Seoul 03080, Korea;
| | - Jin-Mo Yang
- Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea; (D.-S.S.); (H.-Y.K.); (J.-H.K.); (S.-W.L.); (J.-M.Y.)
| | - Jung-Gil Park
- Department of Internal Medicine, Yeungnam University College of Medicine, Daegu 42415, Korea;
| | - Won Kim
- Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul 07061, Korea;
| | - Hyun-Chin Cho
- Department of Internal Medicine, Gyeongsang National University Hospital, Jinju 52727, Korea;
| | - Dong-Joon Kim
- Department of Internal Medicine, Hallym University College of Medicine, Chuncheon 24252, Korea; (J.-H.K.); (K.-T.S.); (H.-S.K.); (D.-J.K.)
- Institute for Liver and Digestive Diseases, Hallym University, Chuncheon 24252, Korea
| |
Collapse
|
9
|
Moon MY, Kim HJ, Kim MJ, Uhm S, Park JW, Suk KT, Park JB, Kim DJ, Kim SE. Rap1 regulates hepatic stellate cell migration through the modulation of RhoA activity in response to TGF‑β1. Int J Mol Med 2019; 44:491-502. [PMID: 31173168 PMCID: PMC6605627 DOI: 10.3892/ijmm.2019.4215] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2018] [Accepted: 05/28/2019] [Indexed: 01/02/2023] Open
Abstract
Although the migration of hepatic stellate cells (HSCs) is important for hepatic fibrosis, the regulation of this migration is poorly understood. Notably, transforming growth factor (TGF)‑β1 induces monocyte migration to sites of injury or inflammation during the early phase, but inhibits cell migration during the late phase. In the present study, the role of transforming protein RhoA signaling in TGF‑β1‑induced HSC migration was investigated. TGF‑β1 was found to increase the protein and mRNA levels of smooth muscle actin and collagen type I in HSC‑T6 cells. The level of RhoA‑GTP in TGF‑β1‑stimulated cells was significantly higher than that in control cells. Furthermore, the phosphorylation of cofilin and formation of filamentous actin (F‑actin) were more marked in TGF‑β1‑stimulated cells than in control cells. Additionally, TGF‑β1 induced the activation of nuclear factor‑κB, and the expression of extracellular matrix proteins and several cytokines in HSC‑T6 cells. The active form of Rap1 (Rap1 V12) suppressed RhoA‑GTP levels, whereas the dominant‑negative form of Rap1 (Rap1 N17) augmented RhoA‑GTP levels. Therefore, the data confirmed that Rap1 regulated the activation of RhoA in TGF‑β1‑stimulated HSC‑T6 cells. These findings suggest that TGF‑β1 regulates Rap1, resulting in the suppression of RhoA, activation of and formation of F‑actin during the migration of HSCs.
Collapse
Affiliation(s)
- Mi-Young Moon
- Department of Internal Medicine, Hallym University Sacred Heart Hospital, College of Medicine, Hallym University, Anyang, Gyeonggi 14068, Republic of Korea
| | - Hee-Jun Kim
- Ilsong Institute of Life Science, Hallym University, Anyang, Gyeonggi 14066, Republic of Korea
| | - Mo-Jong Kim
- Ilsong Institute of Life Science, Hallym University, Anyang, Gyeonggi 14066, Republic of Korea
| | - Sunho Uhm
- Department of Internal Medicine, Hallym University Sacred Heart Hospital, College of Medicine, Hallym University, Anyang, Gyeonggi 14068, Republic of Korea
| | - Ji-Won Park
- Department of Internal Medicine, Hallym University Sacred Heart Hospital, College of Medicine, Hallym University, Anyang, Gyeonggi 14068, Republic of Korea
| | - Ki-Tae Suk
- Department of Internal Medicine, Hallym University Chuncheon Sacred Heart Hospital, College of Medicine, Hallym University, Chuncheon, Gangwon 24253, Republic of Korea
| | - Jae-Bong Park
- Department of Biochemistry, College of Medicine, Hallym University, Chuncheon, Gangwon 24252, Republic of Korea
| | - Dong-Jun Kim
- Department of Internal Medicine, Hallym University Chuncheon Sacred Heart Hospital, College of Medicine, Hallym University, Chuncheon, Gangwon 24253, Republic of Korea
| | - Sung-Eun Kim
- Department of Internal Medicine, Hallym University Sacred Heart Hospital, College of Medicine, Hallym University, Anyang, Gyeonggi 14068, Republic of Korea
| |
Collapse
|
10
|
Suk KT, Mederacke I, Gwak GY, Cho SW, Adeyemi A, Friedman R, Schwabe RF. Opposite roles of cannabinoid receptors 1 and 2 in hepatocarcinogenesis. Gut 2016; 65:1721-32. [PMID: 27196571 PMCID: PMC6594387 DOI: 10.1136/gutjnl-2015-310212] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/21/2015] [Accepted: 04/19/2016] [Indexed: 02/07/2023]
Abstract
OBJECTIVE The endocannabinoid system (ECS) exerts key roles in the development of liver fibrosis and fatty liver, two diseases that promote the development of hepatocellular carcinoma (HCC). Although cannabinoids exert potent antitumour effects in vitro, the contribution of the ECS to carcinogenesis in vivo remains elusive. DESIGN Expression of key components of the ECS, including endocannanabinoids, endocannabinoid-degrading enzymes and endocannabinoid receptors, was determined in healthy liver and tumours. Diethylnitrosamine-induced hepatocarcinogenesis was determined in mice deficient in fatty acid amide hydrolase (FAAH), the main anandamide (AEA)-degrading enzyme, in cannabinoid receptor (CB)1, CB2, or transient receptor potential cation channel subfamily V member 1 (TRPV1)-deficient mice. RESULTS Murine and human HCCs displayed activation of the ECS with strongly elevated expression of CB1 and CB2 but only moderately altered endocannabinoid levels. Contrary to the antitumour effects of cannabinoids in vitro, we observed increased hepatocarcinogenesis in FAAH-deficient mice, a mouse model with increased AEA levels. Accordingly, inactivation of CB1, the main receptor for AEA, in wild-type or FAAH-deficient mice suppressed hepatocarcinogenesis. In contrast, inactivation of CB2 increased hepatocarcinogenesis. CB1 was strongly expressed within HCC lesions and its inactivation suppressed proliferation and liver fibrosis. CB2 was predominantly expressed in macrophages. CB2 inactivation decreased the expression of T-cell-recruiting chemokines and inhibited hepatic T-cell recruitment including particular CD4+ T cells, a population with known antitumour effects in HCC. TRPV1 deletion did not alter HCC development. CONCLUSIONS Similar to their role in fibrogenesis, CB1 and CB2 exert opposite effects on hepatocarcinogenesis and may provide novel therapeutic targets.
Collapse
Affiliation(s)
- Ki-Tae Suk
- Department of Medicine, Columbia University, New York, NY 10032, USA,Department of Internal Medicine, Hallym University College of Medicine, Chuncheon 200704, South Korea
| | - Ingmar Mederacke
- Department of Medicine, Columbia University, New York, NY 10032, USA,Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, 30625 Hannover, Germany
| | - Geum-Youn Gwak
- Department of Medicine, Columbia University, New York, NY 10032, USA,Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135710, South Korea
| | - Sung Won Cho
- Department of Gastroenterology, Ajou University School of Medicine, Suwon 443380, South Korea
| | - Adebowale Adeyemi
- Department of Medicine, Columbia University, New York, NY 10032, USA
| | - Richard Friedman
- Herbert Irving Comprehensive Cancer Center and Department of Biomedical Informatics, Columbia University, New York, NY 10032, USA
| | - Robert F. Schwabe
- Department of Medicine, Columbia University, New York, NY 10032, USA,Institute of Human Nutrition, Columbia University, New York, NY 10032, USA
| |
Collapse
|
11
|
Kim YS, Kim SJ, Yoon JH, Suk KT, Kim JB, Kim DJ, Kim DY, Min HJ, Park SH, Shin WG, Kim KH, Kim HY, Baik GH. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. Aliment Pharmacol Ther 2011; 34:1098-105. [PMID: 21923713 DOI: 10.1111/j.1365-2036.2011.04843.x] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND The eradication rates of Helicobacter pylori (H. pylori) using a proton pump inhibitor (PPI)-based triple therapy have declined due to antibiotic resistance worldwide. AIM To compare the eradication rate of the 10-day sequential therapy for H. pylori infection with that of the 14-day standard PPI-based triple therapy. METHODS This was a prospective, randomised, controlled study. A total of 409 patients with H. pylori infection were randomly assigned to receive either the 10-day sequential therapy regimen, which consisted of pantoprazole (40 mg) plus amoxicillin (1000 mg) twice a day for 5 days, then pantoprazole (40 mg) with clarithromycin (500 mg) and metronidazole (500 mg) twice a day for another five consecutive days or the 14-day PPI-based triple therapy regimen, which consisted of pantoprazole (40 mg) with amoxicillin (1000 mg) and clarithromycin (500 mg) twice a day for 14 days. The pre- and post-treatment H. pylori status were assessed by rapid urease test, urea breath test, or histology. Successful eradication was confirmed at least 4 weeks after finishing the treatment. RESULTS In the intention-to-treat analysis, the eradication rates of the 10-day sequential therapy and of the 14-day PPI-based triple therapy were 85.9% (176/205) and 75.0% (153/205), respectively (P = 0.006). In the per-protocol analysis, the eradication rates were 92.6% (175/205) and 85% (153/204), respectively (P = 0.019). There was no statistically significant difference between the two investigated groups regarding the occurrence of adverse event rates (18.9% vs. 13.3%, P = 0.143). CONCLUSION The 10-day sequential therapy achieved significantly higher eradication rates than the 14-day standard PPI-based triple therapy in Korea.
Collapse
Affiliation(s)
- Y S Kim
- Department of Internal Medicine, Hallym University College of Medicine, South Korea
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Ahn EH, Kim DW, Kim DS, Woo SJ, Kim HR, Kim J, Lim SS, Kang TC, Kim DJ, Suk KT, Park JS, Luo Q, Eum WS, Hwang HS, Choi SY. Levosulpiride, (S)-(-)-5-Aminosulfonyl-N-[(1-ethyl-2-pyrrolidinyl) methyl]-2-methoxybenzamide, enhances the transduction efficiency of PEP-1-ribosomal protein S3 in vitro and in vivo. BMB Rep 2011; 44:329-34. [DOI: 10.5483/bmbrep.2011.44.5.329] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
13
|
Suk KT, Kim HS. [Biomarkers for colorectal cancer treatment]. Korean J Gastroenterol 2009; 53:68-75. [PMID: 19237831] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Individualized tailored therapy is a currently pursuing direction for improving the outcome of patients with colorectal cancer. Targeted therapy is the potential strategy to reach this goal by evaluating status of the presumed targets and their related effector molecules and by maximizing the efficacy of chemotherapeutic agents with less toxicity in individual patient. Numerous hurdles should be overcome, however, because therapeutic outcome can be affected by multiple components; tumor characteristics such as somatic mutations at the DNA, RNA, and protein levels; patient characteristics like germline genetic polymorphisms in enzymes linked to drug metabolism; and environmental factors that include diet and physical activity. Currently, large numbers of potential biomarkers have been proposed but have not yet accomplished supporting evidences for their routine usage in clinics. Therefore, clinical trials driven by molecular targets and relevant biomarkers for the understanding of the conflicting data are needed to make markers available in clinical practice.
Collapse
Affiliation(s)
- Ki-Tae Suk
- Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea
| | | |
Collapse
|
14
|
Suk KT, Nitta A, Konoshima M. [Studies on origin of Japanese Chuanxiong. V. Conioselinum]. YAKUGAKU ZASSHI 1974; 94:1265-9. [PMID: 4477590 DOI: 10.1248/yakushi1947.94.10_1265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
|
15
|
|
16
|
|
17
|
|
18
|
|